Amyotrophic Lateral Sclerosis 2018-2027: Competitive Landscape, Market Insights, and Epidemiology - ResearchAndMarkets.com

DUBLIN--()--The "Amyotrophic Lateral Sclerosis - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive insights about marketed and pipeline drugs across this indication. The report covers an overview of the disease along with global historical and forecasted epidemiological data of Amyotrophic Lateral Sclerosis for the seven major markets i.e. United States, EU5 (France, Germany, Italy, Spain, UK) and Japan till 2027.

Details about the current treatment practices and guidelines provided by the regulatory bodies of US and Europe. This report further provides comprehensive insights about the pipeline drugs. It covers all the clinical pipeline drug profiles and their comparative analysis. Furthermore, the report provides the detailed analysis of 70+ products along with 65+ companies involved.

Products covered by Phase

  • Marketed Products
  • Filed, Phase III, Phase II and Phase I
  • Pre-clinical and Discovery

Overview of pipeline development activities for Amyotrophic Lateral Sclerosis

  • Pipeline analysis of 70+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.
  • Therapeutic segmentation of products for Amyotrophic Lateral Sclerosis
  • The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.

Scope

  • The report provides competitive pipeline landscape of Amyotrophic Lateral Sclerosis
  • The report provides the marketed drugs information including its sales, development activities and details of patent expiry
  • The report provides the insight of current and future market for Amyotrophic Lateral Sclerosis
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Amyotrophic Lateral Sclerosis and also provide company profiling
  • Pipeline products coverage based on various stages of development ranging from late stage till discovery stage
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Companies Mentioned

  • 2-BBB Medicines
  • AB Science
  • BioCrea
  • Biogen
  • Biohaven Pharmaceuticals
  • Ceregen
  • Chemigen
  • Chronos Therapeutics
  • Corcept Therapeutics
  • Coyote Pharmaceuticals
  • Cytokinetics
  • Daval International
  • Edison Pharmaceuticals
  • Genentech
  • Genervon Biopharmaceuticals
  • GeNeuro
  • Grifols
  • Herantis Pharma
  • ImStar Therapeutics
  • Ionis Pharmaceuticals
  • LifeSplice
  • Mallinckrodt
  • Neurimmune Holding
  • Orion Pharma
  • Orphazyme
  • Pharnext
  • Plex Pharmaceuticals
  • ProMIS Neurosciences
  • SciFluor Life Sciences
  • SK Biopharmaceuticals
  • Tarix Orphan
  • ViroMed
  • Voyager Therapeutics
  • Xencor
  • YooYoung Pharmaceuticals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/rr5b4f/amyotrophic?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs